Elastic NV vs uniQure N.V. Ordinary Shares — how do they compare? Elastic NV trades at $90.77 (market cap $9.67B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.45B). The key difference: Elastic NV is far larger — about 6.7× uniQure N.V. Ordinary Shares's market cap, and Elastic NV is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Elastic NV for 11 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| ESTC | QURE | |
|---|---|---|
Market Cap | $9.67B | $1.45B |
Volume | 1,592,425 | 3,323,243 |
Sector | Technology | Health |
52-Week High | $99.91 | $70.59 |
52-Week Low | $43.30 | $9.03 |
Typical Hold Time | 11 Days | 0 Days |
Enterprise Value | $8.80B | $707.46M |
Signals from Pluang's Aura AI — not financial advice
Elastic (ESTC) trades at $94.32, down 1.26% on the day, with a bullish technical signal from moving averages and strong analyst support. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Recent product launches, including a metrics platform and serverless vector database, highlight innovation in AI and data search. Revenue grew to $1.48 billion in 2025, with a projected increase to $1.8 billion in 2026, though 2025 net income was negative.
The outlook is positive, driven by product innovation and earnings beats, but high valuation ratios and negative net income in 2025 pose risks. Analyst consensus is bullish with a $83.18 price target, suggesting potential upside. Key risks include execution challenges and competitive pressures in the software sector.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →